SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

USFDA concludes inspection at Cipla’s Goa manufacturing facility

18 Apr 2026 Evaluate

United States Food and Drug Administration (USFDA) has completed an inspection at Cipla’s manufacturing facility in Verna, Goa, India. The inspection was a routine current Good Manufacturing Practices (cGMP) inspection and a Pre-Approval Inspection (PAI). USFDA had conducted the inspection at said facility from April 06 to April 17, 2025.

On conclusion of the inspection, the Company received two inspectional observations in Form 483. The Company will work closely with the USFDA and is committed to address these comprehensively within stipulated time.

Cipla is in the business of manufacturing, developing, and marketing wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs).

Cipla Share Price

1228.90 -9.40 (-0.76%)
20-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1668.00
Dr. Reddys Lab 1232.25
Cipla 1228.90
Zydus Lifesciences 936.35
Lupin 2328.60
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×